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Abbreviations  
 
PD: Parkinson’s disease 
S: alpha-synuclein 
LB: Lewy Body 
LN: Lewy Neurite 
ER: endoplasmic reticulum 
Tg: transgenic 
ER/M: ER/microsomal 
HMW: high molecular weight  
SpC: spinal cord 
WT: wild-type 
AD: Alzheimer’s disease 
SNpc: substantia nigra pars compacta 
LC: locus coeruleus 
MPTP: 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine  
NAC: non-A component  
Aa: aminoacids 
ROS: oxygen reactive species  
6-OHDA: 6-hydroxydopamine  
UPS: ubiquitin-proteasome system  
UPR: unfolded protein response   
Tx-100: Triton x-100  
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O/N: over/night  
RT: room temperature 
PBS-T: PBS-Tween 
FBS: fetal bovine serum 
DIV: days in vitro 
WGA: weat germ agglutinin 
PFA: paraformaldehyde  
TdT: Terminal Deoxynucleotidyl Transferase  
T-REx™ system: tetracycline-regulated mammalian expression system  
RA: retinoic acid 
PTM: post-translational modification 
n-Tg: non-transgenic 
Ctx: cortex 
IB: immunoblot 
SEM: standard error mean 
Ctr: control 
Tx-S: Tx-Soluble 
Tx-P: Tx-Pellet  
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1. Abstract 
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Parkinson’s disease (PD) is an irreversible and progressive neurodegenerative movement disorder, 
characterized by the abnormal accumulation of alpha-synuclein (S) in the brain, in the form of 
insoluble inclusions called Lewy Bodies (LBs) or Lewy Neurites (LNs). S is a small protein (140 
aminoacid residues), natively unfolded and with a propensity to aggregate. Although it is still under 
debate whether S transient oligomers or mature aggregates are toxic, accumulation of S 
oligomers along the endoplasmic reticulum (ER) membrane, precedes fibrils formation and 
neuronal degeneration in a mouse transgenic (Tg) model of PD.  
The aim of the project was to evaluate the toxic impact of  ER/microsomal (ER/M) -associated S 
oligomers in different cell models. 
S high molecular weight species (HMW) obtained from diseased and presymptomatic Tg mice 
that express human mutant A53T S, was subdivided in two separate fractions with differential 
centrifugation according to their molecular weight and named P10 and P100. P10 represents a crude 
membrane pellet fraction that sediments at 10,000 × g, containing the majority of S aggregated 
species and is rich in mitochondria and synaptosomes. P100 is the microsomal pellet, a fraction that 
sediments at 100,000 × g and is rich in ER, Golgi and synaptic vesicles. P10 and P100 fractions 
were then biochemically characterized by screening with western blot. We found that by 
comparison with non-microsomal associated S (P10), the ER/M-associated S strains (P100) are a 
unique population of S species with specific biochemical traits such as an increase in aggregation, 
N- and C-terminal truncation and phosphorylation at Ser129.   
The aggregates were then administered to a stable and inducible cell model expressing wild-type 
(WT) S or to mouse primary neuronal culture directly in the medium, in order to evaluate the 
cytotoxic effects. After administration, S HMW species were readily taken up from primary 
neurons but not from S inducible cell model. Internalization of P100 but not P10, by neurons 
induced the formation, at first, of small deposits along the neurites, that became longer strings of 
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aggregates at later stages covering the entire process. Increasing the amount of P100/M fractions 
obtained from diseased and, more surprisingly, from presymptomatic mice induced a significant 
level of neuronal death and there they triggered the formation of S endogenous aggregates, that 
ultimately led to cells death. 
These data provide the first evidence of the existence of two different populations of S HMW 
species in vivo, putting the spotlight of the association to ER/M membrane as a necessary step for 
the acquisition of S toxic features. 
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     2.1-synucleinopathies 
 
-synucleinopathies are neurodegenerative diseases characterized by the abnormal accumulation of 
intracellular proteinaceous inclusions made for the most part of aggregated S. PD, Dementia with 
Lewy bodies (DLB) and Multiple System Atrophy (MSA) are the most recurrent -
synucleinopathies.   
  
2.1.1 Parkinson’s Disease  
 
PD is the second most common neurodegenerative disorder of the human brain, after Alzheimer’s 
disease (AD) and the main motor disorder. It is an irreversible and slowly progressive 
neurodegenerative movement disorder, that impairs movement control. The incidence increases 
with aging: from 20 cases out per 100,000 person-years in the world male population, it reaches 120 
cases out per 100,000 person-years in the male population over 70 years of age (industrialized 
countries). The cardinal symptoms, according to which a diagnosis is made, are the appearance of 
four specific motor symptoms including rigidity, resting tremor, bradykinesia and postural 
instability. Although PD is known as a motor dysfunction, there is a broad range of non-motor 
symptoms presented by the patients that include impaired olfactory functions, rapid eye movement 
(REM) sleep behavior disorder (RBD), autonomic dysfunctions (e.g. gastrointestinal symptoms as 
constipation, occurring 20 or more years before the onset of motor-symptoms) and depression that 
represent an early manifestation of PD (Postuma et al., 2012). Dementia is another non-motor 
symptom appearing especially in advanced cases of PD (Goedert et al., 2013). 
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The classical pathological hallmarks underlying the clinical manifestation of the disease are the loss 
of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the appearance of S 
positive intraneuronal inclusions called LBs or LNs according to their cellular location (Fig.1) 
(Galvin et al., 1999; Goedert et al., 2013). LBs and LNs are cellular inclusions discovered by Lewy 
mainly composed by fibrillar aggregates of post-translationally modified S. Apart from the 
presence of S aggregates, the total biochemical composition of LBs and LNs is still unknown 
(Spillantini et al., 1997; Mercado et al., 2013).  
 
                
Figure 1. Left: A representative picture of PD brain versus normal brain shows the lack of 
pigmented dopaminergic neurons in PD. Right: A neuron from the SNpc of a PD patient (from the 
MRC Cambridge Brain Bank) immunostained for S showing two S-positive LBs (Spillantini et 
al., 1997). 
 
      2.1.1.1    Neuroanatomy of PD 
 
Dopaminergic neuronal loss in SN results in a severe and gradual depletion of dopamine content in 
the striatum, a phenomena that is responsible for the motor symptoms. The net consequence of 
dopamine depletion in PD is hypokinesia, an overall reduction of motor outputs. The proper 
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execution of voluntary movements is due to the correct processing of sensory-motor information in 
the brain, thanks to a complex neural network that includes the cortex, the basal ganglia nuclei and 
the motor thalamus. The main task of the circuit is to process the signals that flow from the cortex, 
to produce an output signal that returns to the cortex, through the thalamus, to modulate movement 
execution. In PD the ability to control voluntary movements is lost as a consequence of changes of 
this sensory motor circuit due to a functional organization of the basal ganglia nuclei, to which the 
SN belongs. In fact, the basal ganglia, which are located in the basal telencephalon, consist of five 
interconnected nuclei: the caudate nucleus, the putamen (together referred to as striatum), the 
globus pallidus, the SN and the subthalamic nucleus. The SN is represented by two distinct 
structures, the SNpc and the SN pars reticulate (SNpr). Neurons in the SNpc contain neuromelanin 
and use dopamine as neurotransmitter. The main recipients of nigral projections are the striatum, 
subthalamic nucleus and globus pallidus. In PD the loss of dopaminergic neurons in SNpc affects 
only the nigrostriatal circuit, which is part of the sensitive-motor circuit, and leads to a severe 
dopaminergic denervation of the striatum (Blandini et al., 2000; Fig. 2). 
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Figure 2. Schematic diagram illustrating the changes occurring in the basal ganglia functional 
organization in Parkinson's disease, with respect to normal condition. Relative thickness of arrows 
indicate the degrees of activation of the transmitter pathways. MGP: medial globus pallidus, LGP: 
lateral globus pallidus; SNc: substantia nigra pars compacta; SNr: substantia pars reticulata; STN: 
subthalamic nucleus (Blandini et al., 2000). 
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Striatal denervation triggers, in turns, a cascade of events that leads, ultimately, to the increased 
activity of basal ganglia output nuclei, resulting in an increased inhibitory control over the motor 
thalamus and subsequently reduction of the thalamic glutamatergic excitation to the motor cortex. 
These changes are thought to represent the neural substrate for parkinsonian motor symptoms 
(Blandini et al., 2000). 
Besides voluntary movements, dopamine can control higher brain functions such as motivated 
behaviors and of emotional states. While changes in these latter circuits could partially explain 
certain non-motor symptoms in PD, recently it has been shown how neuronal loss is not limited to 
dopaminergic neurons in SN only but affects other neuronal populations such as serotoninergic 
neurons in the locus coeruleus (LC) and raphe and cholinergic neurons in the basal forebrain (Braak 
et al, 2003; Bohnen et Albin, 2011). Thus it is generally thought that loss of cholinergic neuronal 
populations in specific areas might be responsible for non-motor symptoms such as memory loss 
and cognitive dysfunction, while serotonergic deficits underlie depression and mood disturbances 
and adrenergic deficits underlie attention dysfunction (Pillon et al., 1989). Furthermore recent data 
seem to suggest that the pathology does not initiate with dopaminergic neuronal dysfunction in 
SNpc but in other peripheral areas such as the enteric nervous system, the olfactory bulb, motor 
nuclei in the vagal nerve and/or neuronal populations like serotonergic cells in LC became primarily 
affected (see Braak hypothesis in section 2.2.5, page 29). 
 
2.1.1.2    PD etiology 
 
PD is a multifactorial disorder. Although a specific cause has not been identified yet it is thought 
that aging, environmental factors and genetics have a role in causing PD.  
As for environmental causes it has been described how heavy exposure to certain pesticides (e.g. 
rotenone, paraquat, maneb), to heavy metals (e.g. Fe, Mn, Cu), to toxins such as 1-methyl-4-
phenyl-1,2,3,6 tetrahydropyridine (MPTP) can lead to PD (Polito et al., 2016; Blandini et al., 2000).  
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As regard the genetics risk, we can distinguish the hereditary or familial form, which account for 
about less than 5-10% of total cases, and the idiopathic or sporadic form. Several gene locus have 
been associated so far with the hereditary form of PD. Mutations in the S (SNCA) and Lrkk2 
genes account for the majority of genetic PD pedigree identified so far and are responsible for the 
autosomal-dominant transmission of the disease. In most of the familial autosomal-dominant cases, 
PD symptomatology and pathogenesis does not differ from the sporadic form. Autosomal-recessive 
forms of PD have been also described. The most frequent is associated with mutations in the Parkin 
gene. Transmission of this form of PD is more rare and different from sporadic or other genetic 
cases because associated with a juvenile onset in life (before 30-40 years of age) and an autosomal- 
recessive transmission (Fig. 3).  
Variants in several PARK-designated genes (SNCA, UCHL1, LRRK2, PARK 16, GAK) and a few 
others (MAPT, GBA, NAT2, INOS2A, GAK, HLA-DRA, and APOE) have also been associated 
with an increased risk and genetic predisposition of developing PD, even in case of the sporadic 
disease. Interestingly, polymorphic length and SNP variations in SNCA have repeatedly been 
shown to be among the most significant PD risk factors, closely followed by the occurrence of the 
p.G2385R and p.R1628P missense SNPs in the LRRK2 gene. In addition to SNCA and LRRK2 that 
can be involved both in monogenic disease and act as a risk factor, β-glucocerebrosidase (GBA) 
mutations deserves special attention as a well-validated PD-associated risk factor (Klein et 
Westenberger, 2012).                                                  
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Figure 3. PARK loci and identified genes that segregate with familial forms of PD. Only the loci in 
blue are known to be linked to the monogenic disease. The most studied point mutations in SNCA 
gene are A53T, A30P and E46K. Heterozygous mutations in the leucine-rich repeat kinase 2 
(LRRK2) gene are responsible for the autosomal-dominant PD (Zimprich et al., 2004). 
Heterozygous loss-of-function mutations in PARK2 gene, responsible for the autosomal-recessive 
PD. It codifies for the E3 ubiquitin ligase. Because of its early onset (before the age of 30-40 years) 
it is also called juvenile PD (Kitada T. et al., 1998; Valente et al., 2004). 
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2.2-synuclein 
 
2.2.1 The protein 

S is a small cytosolic protein (140 aminoacid residues,  14 kDa), natively unfolded with                                   
a propensity to aggregate. It is characterized by the lack of rigid, well-defined 3-D structure and 
possesses remarkable conformational plasticity (Bendor et al., 2013). It has been found mainly in 
the neurons, although several non-neural tissues including red blood cells expresses S (Barbour et 
al., 2008). Three S isoforms are produced in humans by alternative splicing and the best-known is 
S-140 (Beyer 2006). S was originally identified using an antiserum against purified cholinergic 
synaptic vesicles from the Torpedo electric organ (Maroteaux et al. 1988), providing the first 
evidence of a presynaptic localization and function. The protein was also identified through the 
biochemical characterization of senile plaques in AD and although not as abundant as the A 
peptide, a fragment from the middle of S (residues 61-95), termed non-A component (NAC) 
accumulates at high levels in AD’s plaques. It was also identified as an inhibitor of phospholipase 
D2 (PLD2), the enzyme implicated in membrane trafficking, particularly regulated exocytosis 
(Bendor, 2013). S is codifying by the gene SNCA on chromosome 4q21 and contains 10 exons.                                                                                           
There are three fundamental domains in the protein (Fig. 4):  
 
~ a N-terminal domain (residues 1-60) containing seven 11 residue repeats with a highly 
conserved hexameric motif (KTKEGV), that are predicted to form an amphipathic -helix 
and it is important for membranes binding. This domain seems to serve also as a hidden 
mitochondrial targeting sequence (MTS), potentially linking S to mitochondrial 
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dysfunctions (Devi et al., 2008). This domain includes the sites of the five familial PD point 
mutation.  
~ A central NAC domain (residues 61-95), highly hydrophobic, implicated in the 
aggregation process (Wang et Hay, 2015). 
~ A polar, with higher proportion of charged residues C-terminal domain (residues 96-140) 
that binds calcium. This domain can be phosphorylated at multiple site (Nielsen et al., 2001) 
and it remains unstructured even in the presence of membranes (Uversky, 2007). 
 
 
 
Figure 4. a) The figure represents the structure of S. Boxed regions 
represent alpha-helices. Seven repeats (residues 10-15, 21-26, 32-37, 43-
48, 58-63, 69-74 and 80-85) in the helical region are depicted with lighter 
shading. PD-associated missense mutations are indicated. It is also 
indicated the Serine129 aminoacidic residue, that is a phosphorylation site 
implicated in S aggregation. The C-terminal region contains a high 
density of charged residues (Wang et Hay, 2015). b) Schematic 
representation of αS. The N-terminal region, NAC region and the C-
terminal part are colored blue, orange and red, respectively. Numbers refer 
to amino acid residues flanking the different regions (Lashuel et al., 2013). 
a) 
b) 
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2.2.2 The physiological role  

S is widely expressed by many neuronal populations within both central and peripheral nervous 
systems, suggesting a general role in neuronal function.                                                        
Although S has been estimated to account for as much as 1% of total protein in soluble cytosolic 
brain fractions, the precise function of this abundant protein remains elusive, like many of the 
proteins that accumulate in other neurodegenerative disorders. S interacts stably with synthetic 
phospholipidic vesicles containing negatively charged head groups, various phospholipid 
membranes, fatty acids, micelles and with biological membranes, such as crude brain vesicles, 
general cellular membranes, lipid rafts and lipid droplet (Fortin et al. 2004). It has been found that 
monomeric S bound to the lipid membrane can efficiently prevent lipid oxidation, possibly 
suggesting that the inhibition of lipid oxidation by S is a physiological function of the protein 
(Zhu et al. 2006).                                                                                                                               
Fractionation of brain extracts reveals a very weak association with synaptic vesicles, thanks to S 
preference for membrane with high curvature (Jensen et al., 2011) even if the vast majority of S 
behaves as a soluble protein (Fortin et al., 2004) and even if the protein do not possess a 
transmembrane domain or a lipid anchor. Although S localizes at presynaptic terminal, it appears 
to be one of the last proteins that localizes to developing synapses, demonstrating that it is not 
essential for synapse development (Withers et al., 1997). In the presynaptic terminal, monomeric 
S exists in an equilibrium between free and plasma membrane- or vesicle-bound states. It seems 
that S can bind membrane vesicles on the cytosolic side but also reside in the vesicle lumen and  
being secreted via exocytosis (Lee et al., 2005). This close association with vesicular structures has 
led to the hypothesis that S may regulate vesicular release and/or turnover and other synaptic 
functions in the central nervous system. For example, it has been shown that the S overexpression 
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inhibits the synaptic vesicles exocytosis (Nemani et al., 2010), even if several of the original 
publications reported that S promoted release (Cabin et al., 2002). It is not already clear how the 
protein is involved in exocytosis, but the most valid hypothesis shows S as a chaperon of SNARE 
complex (Wang et Hay 2015; Burrè et al., 2010; Burrè et al., 2014; Chandra et al., 2005). One 
emerging consensus is that S acts as a SNARE chaperone to potentiate SNARE assembly for 
fusion, promoting SNARE-mediated vesicle fusion in a manner that requires both lipid and SNARE 
interactions. The precise step modulated by S seems to lie slightly upstream of final SNARE 
assembly during clustering, docking and/or SNARE priming for assembly. The SNARE complex is 
made of vesicular SNARE proteins (v-SNARE) and target membrane SNARE proteins (t-SNARE). 
It possesses the ability of self-assembly and allows vesicular fusion to cell membrane. Blocking this 
assembly by αS overexpression interferes with neurotransmitter release and reuptake (Majd et al., 
2015; Fig. 5). Besides being a molecular chaperon for SNARE assembly, S has been recently 
shown to contribute directly to neurotransmitter releaseIn fact a recent study revealed that S 
regulates catecholamine release from the synaptic vesicles and its over-expression inhibits a vesicle 
priming step that occurs after secretory vesicle trafficking to docking sites but before calcium-
dependent vesicle membrane fusion (Larsen et al. 2006). Rosentha and coworkers have shown that 
S knock-out mice exhibited exaggerated levels of dopamine release following stimulation, 
suggesting a modulatory role also for S in dopamine neurotransmission (Abeliovich et al., 2000). 
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Figure 5. αS in normal condition binds to synaptic vesicle membrane and also v-SNARE. v-
SNARE assembly to t-SNARE creates SNARE complex and results in synaptic vesicle fusion to 
cell membrane and neurotransmitter release. αS clusters synaptic vesicles in the axonal terminal and 
produces a high concentration of presynaptic vesicles at a certain area of plasma membrane. 
Vesicular αS also binds to early endosomes and facilitates neurotransmitter refilling of vesicles. αS 
accumulation/fibrillation inhibits vesicular refilling, blocks SNARE complex formation and reduces 
the number of docking neurotransmitter vesicles (Majd et al., 2015). 
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S aggregation  
 
As afore-mentioned, a classical hallmark of sporadic and genetic (mostly the dominant form of PD) 
is the presence of intraneuronal protein inclusions made of aggregated S. 
As revealed by NMR analysis, free S is a typically intrinsic disordered protein, with a remarkable 
conformational plasticity and devoid of a tertiary structure (Eliezer et al., 2001). The structure of S 
is extremely sensitive to its environment and can be easily modulated by a change in conditions. 
The aggregation process is a nucleation-dependent reaction where αS monomer initially forms 
oligomers that are transient intermediate conformations with a spherical ribbon or ring-like shape, 
variable size and shape but still soluble. S then goes through a drastic change in structure, 
becoming tightly packed into -sheet conformers or protofibrils that assemble into amyloid-like 
fibrils or aggregates in the cells (Chu et Kordower, 2015). Mature aggregates are largely insoluble 
and might have two distinct morphologies such as amorphous aggregates and fibrils. S 
dimerization is a key step to form inclusions. The S dimer has a greater propensity to self-interact. 
It acts as a template upon which native S monomers is refolded into protofibrils, the building 
blocks of the aggregates and strongly affects the aggregation properties of the molecules (Chu et 
Kordower, 2015) (Fig. 6). 
Although it is still under debate whether transient oligomers precede fibrils formation or are off-
pathway dead ends in equilibrium with the monomer, several evidences demonstrate that are 
oligomeric intermediates to be actually cytotoxic and not the aggregates (Volles et al., 2001). In fact 
it has been shown how in vitro aggregated S oligomers can modify the permeability of vesicles, by 
formation of pores similar to those generated by pore-forming bacterial toxins (Volles et al., 2001).                                                                          
Numerous factors might contribute to S propensity to aggregate. Mutations in S such as point 
mutations in the N-terminal regions (mutations associated with early onset PD such as A30P and 
A53T) have been shown to favor the oligomerization or fibrillation of the protein, but the 
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unstructured nature of the protein makes it difficult to understand how such mutations could exert 
their effect. Non-polar molecules such as some pesticides that might preferentially bind to the 
partially folded intermediate and cations that might mimic the effect of low pH (high proton 
concentration), as well as other factors that result in an increase in the concentration of S itself or 
that cause a modification of the protein (e.g. via oxidative damage) can all contribute to changes in 
S conformation.  
The C-terminal 40 residues of S appear to lack any secondary structure and can be considered to 
be in a fully random conformation. This lack of structure is maintained in the lipid bound form 
(Eliezer et al., 2010). The presence of weak transient or residual secondary structure in S raises the 
possibility that such structure may play a role in the interactions that lead to S amyloid fibril 
formation, a process which remains poorly understood.  
Even in the absence of any endogenous factors, there is an equilibrium between the natively 
unfolded and the partially folded conformations in S. Therefore, high protein concentration may 
increase the rate of fibrillation due to the increased total concentration of the partially folded 
fibrillation prone intermediate. The concentration of macromolecules (proteins, nucleic acids and 
carbohydrates) within a living cell can be high with the intracellular solutes taking up about a half 
of the total cellular volume. The volume occupied by solutes is unavailable to other molecules, a 
phenomenon known as “excluded volume effects” which may have large effects on the stability of 
biological macromolecules and on macro-molecular equilibria, such as protein-protein interactions 
(Uversky, 2007). It has also been suggested that volume exclusion in physiological media could 
modulate the rate and extent of amyloid formation in vivo.        .                 
Using various subcellular fractions isolated from rat brain homogenate, it has been shown that the 
membrane-bound form has a higher tendency to form aggregates than the cytosolic form (Lee et al., 
2002). Therefore, although it represents only a small fraction of total cellular αS, the membrane-
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bound form may have the ability to give rise to nuclei that seed the aggregation of the far more 
abundant cytosolic αS (Lee et al., 2002).  
At PD later stages, there is an increase in membrane-associated S, with a change in the ratio of 
cytosolic/membrane-associated. Importantly, this intracellular shift and increasing accumulation of 
membrane associated S over time is accompanied by both augmented cytosolic Ser129 S 
phosphorylation (see section 2.2.4, page 25) and insolubility. Also post-translational modifications 
can affect S propensity to aggregate.  
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Figure 6. Events in αS toxicity. The central panel shows the major pathway for protein aggregation. 
Monomeric S is natively unfolded in solution but can also bind to membranes in an -helical 
form. It seems likely that these two species exist in equilibrium within the cell, although this is 
unproven. From in vitro work, it is clear that unfolded monomer can aggregate first into small 
protofibrils species that can be stabilized by β-sheet-like interactions and then into higher molecular 
weight insoluble fibrils. In a cellular context, there is some evidence that the presence of lipids can 
promote oligomer formation: S can also form annular, pore-like structures that interact with 
membranes. The deposition of S into pathological structures such as LBs and LNs is probably a 
late event that occurs in specific neurons. On the left hand side are some of the known modifiers of 
this process. On the right there are some of the proposed cellular targets for S mediated toxicity 
(Cookson et al., 2009). 
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2.2.4  Post-translational modifications 
 
S has been shown to undergo a variety of post-translational modification, which impact its 
aggregation and oligomers formation in different ways. 
 Phosphorylation 
Protein phosphorylation is the most common and probably the most important post-translational 
protein modification. S is constitutively phosphorylated at serine residues, with Ser129 as the S 
major phosphorylation site. Recently, a second S phosphorylation site was identified at Ser87 
(Fig. 7). 
 
 
Figure 7. S ubiquitination and phosphorylation sites. Slightly light green squares show the three 
main ubiquitination sites at K12, K21, and K23; dark green squares show the main S 
phosphorylation sites at S87 and S129 (Beyer et Ariza, 2013). 
 
Immunohistochemical and biochemical studies have shown that a large percentage (~90%) of S 
deposited in LBs is phosphorylated at Ser129 and the proportion of phosphorylated αS in normal 
brain is only 4% of total S, suggesting that accumulation of Ser129-phosphorylated S is involved 
in the formation of LBs and neurodegeneration associated with PD (Fujiwara et al., 2002; Zhou et 
al., 2011). Several kinases mediating S serine phosphorylation have been identified. Casein 
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kinases (CK) I and II, G protein-coupled receptor kinases (GRK1, GRK2, GRK5, and GRK6), 
calmodulin-dependent kinase (CDK) II, polo-like kinase (PLK) 2 and 3 are all being possible 
candidate to  phosphorylate S at S129. Controversial effect of S129-phosphorylated on S 
propensity to aggregate has been described and it seems to depend on the specific kinase used in the 
study. In fact, the specific phosphorylation of S at S129 by CK II and GRK6 resulted in 
accelerated oligomerization, fibrillation and neurodegeneration (Fujiwara et al. 2002; Sato et. Al, 
2011). Contrarily, phosphorylation of S at S129 by CK1 blocks S fibrillation (Paleologou et al., 
2008). These findings suggest that phosphorylation inhibits, rather than promotes, LB formation in 
vivo. The fact that Ser129 undergoes phosphorylation by CK1 in the fibrillar S state means that 
phosphorylation occurs after S fibrillation and/or during the development and maturation of LBs 
(Paleologou et al., 2008).  
 
 Ubiquitination 
Ubiquitination is a fundamental biochemical process that controls numerous aspects of protein 
function, such as degradation, protein-protein interaction and subcellular localization. It is has been 
repeatedly shown that S purified from LBs is partly ubiquitinated. S contains 15 lysine residues 
and although four of them (K21, K23, K32, and K34, at the N-terminal) were found to be liable to 
ubiquitination in vitro, S ubiquitination in vivo occurs at the K6, K10, and K12 residues (Nonaka 
et al., 2005) (Fig. 7). Ubiquitination of αS causes changes in αS function/activity, impacting on αS 
localization and αS degradation processes. Ubiquitination of aggregated or filamentous proteins has 
been implicated in the pathogenesis of many neurodegenerative diseases (Nonaka et al., 2005). 
Intracellular inclusion bodies such as nuclear inclusion bodies, composed of expanded 
polyglutamine repeats in many polyglutamine diseases, neurofibrillary tangles comprised of 
hyperphosphorylated tau in AD, LBs and related inclusions made of hyperphosphorylated S in -
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synucleinopathies have been shown to be ubiquitin-positive (Nonaka et al., 2005). Genetic studies 
have also demonstrated that dysfunction of proteins related in the ubiquitin-proteasome pathway 
causes neurodegeneration. S ubiquitination promoted by SIAH-2, an E3 ubiquitin-ligase that 
mono- and diubiquitinate and monoubiquitinate S in vivo respectively, is similar to the 
endogenous ubiquitination pattern observed in biochemically purified LBs and may involve 
residues K12, K21, and K23. Under conditions of proteasomal impairment, SIAH-1, another E3 
ubiquitin-ligase, enhances S aggregation and promotes apoptotic cell death by S ubiquitination 
(Beyer et Ariza, 2013; Rott et al., 2007). 
 
 Nitration and oxidation 
Oxidative injury occurs when the compensatory antioxidant capacity of the brain is overwhelmed 
by production of reactive oxygen species. A common effect of increased oxidative stress is the 
nitration of tyrosine residues by peroxynitrite, a product of the reaction of oxygen and nitric oxide. 
S sequence contains four tyrosine residues (Y39, Y125, Y133, and Y136; Danielson et al., 2009) 
that undergo nitration in conditions of enhanced oxidative stress, as well as four methionine 
residues (M1, M5, M116, and M127) that are modified by oxidation (Barrett and Greenamyre, 
2015; Beyer et Ariza, 2013; Fig. 8). 
 
 
Figure 8. S nitration and oxidation sites. Light orange squares indicate the four AS oxidation sites 
and blue squares the four nitration sites (Beyer et Ariza, 2013). 
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The higher oxidative stress levels in dopaminergic neurons are claimed to be a primary cause of PD 
development. LBs contain high levels of nitrated S and this finding encouraged the research for 
the causes and mechanisms of S nitration. The administration of nitrated S to the SNpc of rats 
caused severe reductions in the number of dopaminergic neurons (Yu et al., 2010) and in culture 
cells  induced apoptosis in a dose-dependent manner through nitrated S oligomers formation (Liu 
et al. 2011).  
 
 Truncation 
S undergoes C-terminal and N-terminal truncation in vivo. At least 3 main truncated fragments 
have been identified in vivo that include Syn12 and Syn10 that are the result of C-terminal 
truncation around aminoacids (aa) 120 and 110, respectively and Syn8 which is truncated at N and 
C-terminal leaving a shorter protein of around 80 aa. While Syn12 and Syn10 are found in both 
soluble and insoluble detergent fraction in mouse and human brains, Syn8 is associated only with 
the insoluble aggregates, both in mouse and human brains. Moreover, while accumulation of Syn12 
and Syn10 appears to be independent of S aggregation, accumulation of Syn8 seems to require the 
antecedent aggregation of S, whereas the other two forms accumulation. The characterization of 
the C-terminal peptides allowed to identify Asp119-Pro120 and Asn122-Glu123 as the sites of 
cleavages for Syn12, cleaved by the 20S proteasome and by Calpain I respectively (Li et al., 2005). 
Thus, S truncation may be mediated by more than one proteolytic system, included also Cathepsin 
D, Neurosin, Matrix Metalloprotease 3 (Li et al., 2005; Beyer et Ariza, 2013). Accumulation of C-
terminal truncated fragments Syn12 and Syn10 is a normal physiological process (Li et al., 2005), 
although the familial PD mutations are associated with the higher cellular accumulation of truncated 
S. Human cases with S lesions show preferential accumulation of truncated S in aggregates and 
higher relative levels of soluble truncated S. It has been repeatedly demonstrated that these 
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truncated S species enhance S fibril assembly and promote the ability of full-length S to 
aggregate (Li et al., 2005).  
 
2.2.5 Propagation and Prion-like Hypothesis 
 
Because not only dopaminergic neurons in the SNpc are affected in PD, the question arising is 
where and how the pathology initiates. The more accredited hypothesis so far has been formulated 
by Braak and colleagues. Following post-mortem studies, Braak found presence of LB in peripheral 
nervous area such as the gut and dorsal motor nuclei of the vagus, and olfactory bulb in PD patients 
and numerous controls (Braak et al., 2003). He called these control cases with LBs accumulation, 
preclinical or prodromic PD and postulated that S deposits in specific brain regions and neuronal 
types accumulate Lewy pathology in a stereotypic, temporal pattern that ascends caudo-rostrally 
from the periphery such as the nervous innervation of the intestine or the lower brainstem 
(including the dorsal motor nucleus of the vagus nerve in the medulla then the coeruleus-
subcoeruleus complex, raphe nuclei, gigantocellular reticular nucleus in the medulla and pons) or 
anterograde from the olfactory bulb, through susceptible regions of the midbrain (SN and the 
pedunculopontine tegmental nucleus) and forebrain (e.g., amygdala) and into the cerebral cortex 
(e.g., anteromedial temporal mesocortex, cingulate cortex and later neocortical structures). Thus 
according to Braak, PD initiates in the periphery, gaining access to the CNS through antero- or 
retrograde transport along projection neurons from the gastrointestinal tract and from the olfactory 
bulb. Both the lesions in the olfactory bulb and in the enteric plexus could explain prodromic 
symptoms such as hyposmia and constipation. As the disease progresses, the severity of lesions in 
the susceptible regions increases (Braak et al., 2003) (Fig. 9). 
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Figure 9. Stages in the evolution of PD-related pathology. Braak and colleagues summarize the 
evolution of PD in 6 stages, depending on the affected nervous system area. The figure represents a 
time line which lists the main symptoms of the pathology, starting from the prodromic symptoms, 
which occur before the clinical disease onset, until the later symptoms. According to this hypothesis 
the clinical onset of the pathology is given by the exhibition of motor symptoms as tremor, rigidity 
or akinesia (Hawkes et al., 2010). 
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The Braak’s staging suggests a prion-like spread as possible mechanism to explain S propagation. 
His hupothesis suggests that S is capable of transcellular spreading in vivo and has obvious 
implications for the potential of aggregated protein to spread pathology from cell to cell in humans. 
Whether aggregates can transfer directly between cells in vivo is unknown, but cell cultures studies 
suggest this is possible (Desplats et al., 2009). S and its aggregated forms are secreted at low 
levels in neuronal cultures. This secretion is increased under protein misfolding stress, suggesting 
the existence of release mechanisms susceptible to dysregulation under disease conditions (Lee et 
al., 2005). It has been confirmed that cell to cell transmission of S also was mediated by 
endocytosis of recipient cells and that the transmitted S accumulated when the recipient’s 
lysosomes were inhibited. These facts suggest that reduced lysosomal capacity of recipient cells 
may be in part responsible for the deposition of transmitted S. Lysosomal activity decreases with 
aging and mutations in lysosomal hydrolases cause neurodegeneration in several inherited 
lysosomal storage disorders (Desplats et al., 2009). In order to study the pathogenesis of PD it is 
more important to understand whether and how also the aggregates propagate in this way. Several 
evidences, both in vivo and in vitro, demonstrate that this mechanism occurs. It was shown that 
fibrils of recombinant S can enter neurons directly by endocytosis and seed the formation of 
aggregates resembling Lewy pathology in cells that express only endogenous levels of S. The 
fibrils of recombinant S containing only the central, hydrophobic portion of the protein are 
sufficient to seed conversion of endogenous S into pathological aggregates (Volpicelli-Daley et 
al., 2011). S appears also capable of spreading between the cells in vivo. This has been 
demonstrated, since two subjects with PD who had long-term survival of transplanted fetal 
mesencephalic dopaminergic neurons (11-16 years) into an ectopic site developed S-positive LBs 
in grafted neurons (Li et al., 2008). After both subjects death, it has been found that grafted neurons 
had S and ubiquitin-positive LBs and LNs. LBs and LNs resulted also positive to an antibody that 
recognize phosphorylatedS. The most striking finding in both cases was the presence of LBs and 
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LNs in the long-surviving grafted dopaminergic neurons that were morphologically 
indistinguishable from those seen in the SNpc neurons in PD (Li et al., 2008). Others in vitro 
experiments demonstrate the induction of LB-like aggregates in SH-SY5Y cultures by exposure to 
S fibrils and oligomers. At first these two S species drive the aggregation of endogenous S, 
then the cells death (Luk et al., 2009; Nonaka et al., 2010). Finally, synthetic misfolded S 
administered not only leads to cellular death, but also it self-propagates and spreads between 
interconnected central nervous system regions, suggesting that cell to cell transmission of 
pathological proteins contributes to disease progression, generating a degenerative cascade (Luk et 
al., 2012, Peelaerts 2015). Moreover intracerebral inoculation of transgenic mice expressing human 
S with extracts from old mice containing S aggregates or even with in vitro prepared S 
aggregates triggered an early onset of disease (motor alterations and accumulation of protein 
aggregates), compared with uninoculated mice that remained healthy (Mougenot et al., 2012). 
Propagation of misfoldedS between cells follows a model in which misfolded protein travels from 
an infected cell to a naïve cell, whereupon it encounters and converts native protein to misfolded 
(Frost et Diamond, 2010). The limiting step in the aggregation process is nuclei formation and the 
rate of misfolding and aggregation depends upon the number of seeds produced. The key element 
that makes S infectious is its ability to act as a seed to induce the conversion into misfolded 
conformation. 
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Figure 10. Models of cell to cell protein transmission. This diagram illustrates potential 
mechanisms by which misfolded/aggregated proteins are transmitted from one neuron to another. 
Proteins may be released from neurons via vesicle-mediated exocytosis (1) or simple leakage 
through damaged membranes (2) due to pore formation (Volles et al., 2001), then internalize into 
neighboring neurons either via endocytosis or via direct penetration of the membrane. Proteins may 
be transmitted to the neighboring neurons by packaging into exosomes (3) or through tunneling 
nanotubes (4). Some or all of these mechanisms might work simultaneously, with a specific protein 
preferring a certain pathway to others. These mechanisms might act between the cell bodies, but 
could also occur trans-synaptically (5). Internalized aggregates might act as seeds for the 
aggregation of the endogenous native proteins (Lee et al., 2010). 
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The Figure 10 summarizes the possible strategies that drive S propagation (Soto, 2012).                             
Once released, S protein aggregates are internalized through endocytosis and packaged into 
endocytic vesicles. During the course of seeded polymerization, subtle conformational variations in 
aggregates are self-propagated by converting newly added monomers into their particular structures. 
This conformational propagation, characteristic of prion strain, raises the possibility that 
neurodegenerative pathologies involving protein aggregation may spread within the brain via a 
mechanism analogous to prion-like self-propagation (Lee et al., 2010).  
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3.Cell dysfunctions and stress in             
Parkinson’s Disease 
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The mechanisms responsible for neuronal degeneration in PD are complex and remain to be fully 
elucidated. However PD and several other neurodegenerative diseases as AD, Huntington’s disease 
and amyotrophic lateral sclerosis, despite having distinct pathological and clinical features, show 
characteristic pathogenic mechanisms of cells stress that ultimately can lead to cells death. The 
main type of stress occurring in the neurons in disease are the oxidative stress, the mitochondrial 
stress and the endoplasmic reticulum (ER) stress. 
 
3.1   Mitochondrial stress and PD 
 
Mitochondria are dynamic organelles with many functions. Beside their role in energy generation, 
they are closely involved in calcium homeostasis, stress response and cell death, through intrinsic 
apoptosis pathway. Mitochondrial function is impaired in PD at different levels ranging from 
organelle biogenesis, mitochondrial fusion/fission, to mitophagy (Zhu et Chu, 2010). 
The mitochondrial stress is especially due to the presence of oxygen reactive species (ROS) and 
nitrogen reactive species (RNS) in the cells (see section 3.2, page 37). Another source of stress is 
the morphological alteration of mitochondria membranes and the decrease of mitochondria number. 
Several PD related genes have been shown to play critical roles in maintaining normal 
mitochondrial morphology and function, such as PINK, Parkin (Poole et al., 2008). The alteration 
of mitochondria membranes and consequently of the tethering between ER and mitochondria causes 
deregulation of the calcium signal, due to the increasing calcium levels into the cells. This results in 
inappropriate protein folding, metabolic alterations and apoptosis (Rizzuto et al., 2009). 
Mitochondrial autophagy (mitophagy) is a major mechanism for turnover of entire segments of 
mitochondria, although localized protein degradation pathways also exist. Alterations in autophagy 
or mitophagy are observed in several toxin and genetic models of PD, including MPTP, 6-
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hydroxydopamine (6-OHDA), rotenone, PINK1, parkin and dopamine toxicity. Mitophagy 
mechanisms alteration lead to significant dopaminergic neuron loss in the SNpc (Dias et al., 2013).                                                                                                            
Even in case of mitochondrial stress we can link the pathogenesis of PD with misfolded S. 
Functional studies have shown that the binding of S to mitochondria is followed by cytochrome c 
release (the first step for the activation of intrinsic pathway of apoptosis), that lead to increasing 
calcium and ROS levels and ultimately to cell death (Parihar et al., 2008). Accumulation of WT S 
in the mitochondria of human dopaminergic neurons caused reduced mitochondrial complex I 
activity and increased production of ROS (Devi et al., 2008).                
                  
3.2   Oxidative stress and PD  
 
The oxidative stress defines a disequilibrium between the levels of ROS produced and the ability of 
a biological system to detoxify the reactive intermediates. The link between the oxidative stress and 
the degeneration in dopaminergic neurons is supported by postmortem brain analyses showing 
increased levels of 4-hydroxyl-2-nonenal (HNE), a by-product of lipid peroxidation, carbonyl 
modifications of soluble proteins and DNA and RNA oxidation products 8-hydroxy-
deoxyguanosine and 8-hydroxy-guanosine. This link is further supported by modeling the motor 
aspects of PD in animals with toxins that cause oxidative stress including MPTP, rotenone, paraquat 
and 6-OHDA (Dias et al., 2013). ROS can be generated in the brain from several sources, both in 
neurons and glia. The first source of ROS is the electron transport chain that could be impaired by 
MPTP, an inhibitor of complex I of the electrons transport chain. Then ROS also result from 
dopamine metabolism and in particular from dopamine oxidation, monoamine oxidase (MAO), 
NADPH oxidase (NOX), low glutathione (GSH) levels and high levels of iron and calcium in the 
SNpc (Dias et al., 2013). Additionally, the brain contains high concentrations of polyunsaturated 
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fatty acids, which under oxidative stress conditions result in lipid peroxidation and the generation of 
toxic products. Even in case of oxidative stress, misfolded S can be related to PD. For example, 
one possible mechanism can be the increasing of cytosolic catecholamine concentrations, which 
result from the disruption of vesicular membrane integrity by pore forming S protofibrils (Dias et 
al., 2013). The organism develops adaptive responses to oxidative stress that result in increased 
production of defensive enzymes, molecular chaperones and antioxidant molecules. The ubiquitin-
proteasome system (UPS) is the main pathway through which cells degrade and remove damaged 
and unwanted proteins and also S is a substrate of this system. 
 
3.3   ER stress and PD 
 
The ER is the organelle specialized in the proteins folding and in the vesicular transport of those 
proteins correctly folded from the ER to Golgi apparatus. It is also the major intracellular calcium 
reservoir in the cell. The homeostasis of the ER can be altered by a series of conditions including 
calcium depletion from its lumen, oxidative stress and mutations in proteins that traffic through the 
secretory pathway, among other events (Hetz, 2012). All of these perturbations can result in 
disruption of the folding process in the ER, leading to the accumulation of misfolded/unfolded 
proteins. These events carry to the ER stress, that activates the unfolded protein response (UPR), a 
complex signal-transduction pathway that mediates cellular adaptation to restore ER homeostasis. 
Under chronic ER stress the UPR triggers cell death by apoptosis, eliminating damaged cells 
(Mercado et al., 2013). Substantial evidence for a role of the UPR in PD pathogenesis comes from 
the juvenile onset autosomal recessive form of PD. It is caused by mutation of the Parkin gene, 
which compromises the ubiquitin ligase function of the protein. This loss of activity results in 
accumulation of a substrate of Parkin in the ER of SN neurons, leading to ER stress and cell death 
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(Hoozemans et al., 2007). It has been demonstrated the activation and upregulation of some ER 
stress responsive proteins as Herp, Bip, pPRDI and pPERK in the SNpc of patients with sporadic 
PD that colocalize with LBs (Hoozemans et al., 2007; Mercado et al., 2013). Here, the presence of 
these stress sensors together with S suggests a functional connection between S pathology and 
the occurrence of ER stress. S could induce ER stress in different ways (Fig. 11). Overexpression 
of mutant forms of the protein in neuronal cells leads to formation of cytoplasmic aggregates and 
disruption of the UPS. Decreasing protein degradation could increase the protein load in the ER, 
making the cell more vulnerable for ER stress. In yeast models of PD, it was shown that S 
overexpression induces ER stress by disrupting ER-Golgi vesicular trafficking, since impaired 
vesicle transport from the ER triggers the accumulation of immature proteins in this compartment 
(Cooper et al, 2006). Even the induced WT S overespression elicits an ER stress response (Jiang 
et al., 2010). The initial activation of the UPR in PD pathogenesis might have a neuroprotective 
role, in an attempt to remove the neurotoxic unfolded proteins. However, prolonged ER stress and 
UPR activation can overwhelm the cellular protective mechanisms, ultimately triggering cell death, 
through the intrinsic pathway of apoptosis (Hoozemans et al., 2007). Even in a Tg mouse model of 
PD, with A53T S mutation, it was demonstrated the induction of two ER chaperones, grp78 and 
grp94. Probably S conformers sequester these ER chaperones, leading the impaired ER folding 
and chronic stress. Neurons with abnormal S generally exhibit stronger grp78/94 
immunoreactivity (Colla et al., 2012). Because of the colocalization of -synucleinopathy with ER 
chaperone, the activation of ER stress could be caused by direct effects of S or S aggregates on 
ER. In fact, the protein and their aggregated are associated with the ER-enriched microsomes in 
human brain affected by PD and in A53T Tg mice (Colla et al, 2012a), although oligomers and 
aggregates have always been considered to be cytoplasmatic. In particular the protein is located into 
the lumen of the ER and not exposed on the membrane surface (Colla et al., 2012). -
synucleinopathy in A53TS Tg mice is associated with chronic ER stress and overexpression of S 
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sensitizes neural cells to ER stressors. Moreover, in -synucleinopathy, S oligomers accumulation 
precedes the onset of the disease and matures with its progression (Colla et al., 2012a). In fact while 
diseased A53T S mice accumulate both S oligomers and aggregates in isolated microsomes 
fractions, presymptomatic mice only show the presence of S oligomers. Thus formation of S 
oligomers in the ER enriched-microsomal fractions that precedes -synucleinopathy could interfere 
with ER functionality and in turn promote neurodegeneration. UPR activation by S overexpression 
is partially dependent on phosphorylation at Ser129 and S-nitrosylation, suggesting that post-
translational modifications can affect S aggregation and toxicity against the ER (Colla et al., 
2012).  
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Figure 11. Mechanisms underlying the induction of ER stress in PD. The figure summarizes 
different pathological events observed in PD models that trigger ER stress including: S 
accumulation at the ER and interaction with the ER chaperone Bip, local oxidative stress and S-
nitrosylation of protein disulfide-isomerase (PDI), altered ER calcium homeostasis by Herp-
mediated degradation of IP3R and pan-RyR, S inhibition of ER to Golgi trafficking, altered ER-
associated protein degradation (ERAD) and accumulation of mutant LRRK2 or ATP13A2, among 
other indicated mechanisms (Mercado et al., 2013). 
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4.           Aim of the project 
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It has been recently documented that the accumulation of S oligomers/aggregates occurs 
specifically in the ER. Presence of S high molecular weight (HMW) species in this organelle 
correlates to the onset and progression of neurodegeneration in a Tg mouse model for S toxicity 
(human A53T S transgenic mice) (Colla et al., 2012) and it is thought to contribute to the 
induction of ER stress, proteasomes dysfunction and activation of the cell death pathway in this 
model. Thus it appears that the ER may represent a preferential site for initiation and progression of 
S aggregation. Formation of S oligomers and aggregates directly in the ER would favor their 
secretion and represent a possible mechanism for S neuron to neuron transmission, thanks to the 
existence of an ER-Golgi axis (Wang and Hay, 2015). Moreover understanding the ER 
involvement in S aggregation could be an enormous step forward in elucidating S driven 
pathology and provide at the same time a new target for therapy. On the other hand, the results 
reached by Virginia M.-Y. Lee and coworkers (Volpicelli-Daley et al., 2011; Luk et al., 2009) in 
inducing LBs pathology, thanks to S fibrils administration, encouraged to improve the knowledge 
about the mechanisms underlying the S aggregation and transmission. 
The aim of the project was to analyze the functional impact of ER/M-associated S 
oligomers/aggregates. In order to do that I first biochemically characterized ER/M-associated S 
oligomers/aggregates comparing them to the rest of free or membrane-associated S HMW species 
to see if two different populations of S existed in neurons at the same time. Second, I tested 
ER/M-associated S oligomers/aggregates toxicity in a stable and inducible model for S 
expression and in mouse primary neuronal cultures. 
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5.     Material and Methods 
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5.1         Tg mouse model 
 
Tg mice that we used in our studies express high levels of human S carrying the PD-associated 
mutation A53T under the control of the mouse prion protein promoter. This mouse model develops 
fatal neurological disease at ~12 months of age which rapidly progresses to end state within 14-21 
days of onset. At disease onset, the mice exhibit neuronal S and ubiquitinated 
aggregates/inclusions (Lee et al., 2002), degeneration of axons and neuronal loss (Martin et al., 
2006). Presymptomatic mice were taken 9 months old and were free from any motor dysfunction.  
 
5.2          Membrane fractions preparation 
 
Microsomes are vesicle-like artifacts re-formed from pieces of the ER when eukaryotic cells are 
broken-up in laboratory. Microsomes are not present in healthy, living cells, but they can be 
concentrated and separated from other cellular debris by differential centrifugations.                                                                                                                                            
For subcellular fractionation, fresh tissues were homogenized in a 1:10 (w/v) volume of lysis buffer 
that is composed by 250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 2 mM EDTA 
and a phosphatase/protease-inhibitors (cOmplete Mini, EDTA free, and PhosStop, Roche 
Indianapolis-USA) mixture, using a Teflon pestle homogenizer, for 1 minute (~10-15 strokes). 
Initial homogenates were centrifuged at 1,000 × g for 10 minutes at 4°C in order to remove nuclei 
and unbroken cells in the resulting pellet (P1). The resulting supernatant was centrifuged at 10,000 
× g for 20 minutes at 4°C to obtain the first membrane pellet (called P10). P1 and P10 fractions 
have been resuspended in 200 L lysis buffer. The supernatant was centrifuged in an ultracentrifuge 
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(Beckman 90 Ti rotor) at 100,000 × g, for 1 hour. The resulting pellet (P100) contained the 
microsomes. The P100 pellet was washed with lysis buffer and  centrifuged at 10,000 × g for 20 
minutes, at 4°C and finally resuspended in 100 L of lysis buffer (Colla et al., 2012). The samples 
were quantified with Pierce™ BCA Protein Assay Kit.  
 
5.3        Cell lysis and Western blot 
 
Cells were lysed directly on plate or after they are separated from it using trypsin (when they had 
also to be passed), a proteolytic enzyme that breaks down the proteins which allow the cells 
adherence to the dish. Lysis buffer is composed by 10% proteases/phosphatases inhibitors 
(cOmplete Mini, EDTA free, and PhosStop, Roche Indianapolis-USA) and 10% Triton X-100 (Tx-
100) in 1X PBS. After lysis we separated the ionic (soluble) and non-ionic (insoluble) detergent 
fractions with a centrifuge at 16,000 × g for 15 minutes at 4°C. The insoluble fraction was 
resuspended in the lysis buffer with the addition of 1% SDS, subsequently sonicated at maximum 
power and boiled at 95°C for 5 minutes. Total protein content was measured according to the 
Pierce™ BCA Protein Assay Kit procedure (ThermoFisher Scientific, Rockford-USA) using bovine 
serum albumin as calibration standard. Proteins were run under reducing conditions (120 V at room 
temperature, RT) on an SDS-polyacrylamide gel and then electrophoretically transferred onto 
nitrocellulose membrane at 200 mA, over/night (O/N) at 4°C, using carbonate transfer buffer (10 
mM NaHCO3, 3 mM Na2CO3, 20% MeOH). This type of buffer was used to improve the efficiency 
of protein transfer onto the membranes. Transfer efficiency was controlled by Ponceau S staining. 
Unspecific binding sites were blocked by 30 minutes membranes incubation with 5% nonfat dry 
milk (Bio-Rad-USA) in 1X PBS containing 0,01% Tween-20 (PBS-T) at RT. Membranes were then 
incubated with specific primary antibody (see Table 1) dissolved in 2.5% nonfat dry milk in PBS-T, 
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O/N at 4°C. Membranes were washed with PBS-T and incubated for 1 h at RT with the appropriate 
horseradish peroxidase-conjugated secondary antibody (1:3,000 in 2.5% nonfat milk in PBS-T). 
Immunoreactivity was visualized using chemiluminescence detection (SuperSignal
®
 West Pico 
Chemiluminescent Substrate or SuperSignal
®
 West Femto Maximum Sensitivity Substrate, 
ThermoFisher Scientific; Rockford-USA), using a CCD-based Bio-Rad Molecular Imager 
ChemiDoc XRS. The intensitiy of the immunoreactive bands was determined by densitometry using 
the Quantity One software (Bio-Rad). 
                     
5.4          Dot blot 
 
Dot blot analysis was performed under native conditions. 2 g of each samples were spotted 
directly onto nitrocellulose membrane and let dry completely. Unspecific binding sites were 
blocked by 30 minutes membrane incubation with 5% nonfat dry milk (Bio-Rad-USA) in PBS-T at 
RT. Membranes were then incubates with specific primary antibodies (see Table 1), dissolved in 
2.5% nonfat dry milk in PBS-T, O/N at 4°C. Membranes were washed with PBS-T and incubated 
for 1 h at RT with the appropriate horseradish peroxidase-conjugated secondary antibody (1:3,000 
in 2.5% nonfat milk in PBS-T). Immunoreactivity was visualized using chemiluminescence 
detection (SuperSignal
®
 West Pico Chemiluminescent Substrate or SuperSignal
®
 West Femto 
Maximum Sensitivity Substrate, ThermoFisher Scientific; Rockford-USA), using a CCD-based Bio-
Rad Molecular Imager ChemiDoc XRS. The intensity of the immunoreactive bands was determined 
by densitometry using the Quantity One software (Bio-Rad). 
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Table 1. Western Blot and Dot Blot antibodies. 
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5.5         Primary Neuronal Cultures 
 
Primary neuronal cultures were prepared from WT newborn (P0) mouse hippocampus and cortex, 
according to a procedure first described by Beaudoin, that does not use an astroglial feeder cell 
layer (Beaudoin et al. 2012). Hank's Balanced Salt Solution (HBSS; GIBCO
®
, ThermoFisher 
Scientific; Eugene, Oregon-USA) was used as mechanical dissection medium. Tissues mechanically 
dissected were treated with 0.1% trypsin for 7 minutes at 37°C which allows the enzymatic 
dissection. To block trypsin, a medium with FBS and DNase was added to the homogenate. The 
resulting mix of cells and tissue was first centrifuged at 1,000 rpm for 5 minutes and the supernatant 
was removed. The pellet represented the cells dissected from tissue. The cells were resuspended in 
plating medium that contains 2% B27 (GIBCO
®
 ThermoFisher Scientific; Eugene, Oregon-USA), 
1X Glutamax (GIBCO
®
 ThermoFisher Scientific; Eugene, Oregon-USA), 6 mg/mL glucose, 10% 
fetal bovine serum (FBS; Euroclone
®
), 12.5 M glutamate (Life Technologies) and 1X Gentamicin 
(GIBCO
®
 ThermoFisher Scientific; Eugene, Oregon-USA) in 1X Neurobasal
®
Medium (GIBCO
®
 
ThermoFisher Scientific; Eugene, Oregon-USA). Dissociated neurons were then plated onto poly-
D-lysine coated coverslips, previously treated with 64% nitric acid solution O/N. We used 1 
cortex/12 wells and 1 hippocampus/6 wells, resulting in approximately 150,000/200,000 cells per 
well. Neuronal cultures were prepared by pooling tissue from several animals. The cells were 
maintained into the incubator at 37°C. At day in vitro (DIV) 1, the plating medium was removed 
and changed with culture medium that contains 2% B27, 1X gentamicin and 1X Glutamax in 1X 
Neurobasal
®
Medium. At DIV2, 1/3 of medium was removed and 1/3 of fresh medium was added 
with 2.5 M AraC, an antimetabolite that kills cells by inhibiting DNA synthesis. The following 
days, the cells were maintained at 37°C and half of medium was replaced every three days.                                                                          
In Figure 12, I show a picture of cortical neurons at DIV0 in a) and another one at DIV6 in b). We 
can underline how neuronal morphology and arborization develop over time. In fact in a) the 
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neurites are not present, since neurons had just been seeded. In b), neurons develop extensive 
axonal and dendritic arbors and form functional synaptic connections. 
 
            
Figure 12. Representative pictures of cortical neurons. a) DIV0 cortical neurons. b) DIV6 cortical 
neurons. In a) the neurons were just plated into a 24-well plate. In b), after 6 days in culture, the 
neurons are well sticking to the plate and show mature neurites. The images were acquired using an 
Axio Vert.A1 light microscope (Zeiss, Germany). 
  
5.6          Neurons and SH-S WT treatment 
 
Neurons were treated with different subpopulations of aggregates, prepared as previously described 
(see section 5.2 page 48). The treatments were done at 7 days in vitro (DIV). 1/3 of medium was 
changed and the aggregates were administered to the cells directly in the medium. Except for the 
cell survival experiments, where cultures were fixed after induction of apoptosis, in all the other 
studies, cultures were fixed after 2 weeks of treatment. During this time conditioned medium was 
not replaced but was added in small amount (1/3 of the total starting volume) to the cultures every 
a) b) 
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2-3 days. SH-S WT were treated with the same subpopulation of aggregates, except that together 
with pellet fractions cells received 0.1 g/mL of weat germ agglutinin (WGA), which binds N-
acetylglucosamine and sialic acids at the cell surface and thus induces adsorptive mediated 
endocytosis. The aggregates were administered in addition of WGA, 3 days after the induction. 
 
5.7        Immunofluorescence and “two-stages” immunofluorescence 
 
Neurons were fixed with 2% paraformaldehyde (PFA) and 5% sucrose solutions for 15 minutes at 
RT. Then they were permeabilized with 0.3% Tx-100 for 5 minutes at RT. After a 30 minutes 
incubation at RT with 3% FBS, necessary to block unspecific binding sites, neurons were incubated 
with specific primary antibodies (see Table 2) dissolved in 3% FBS, O/N at 4°C. Neurons were 
washed in PBS and then incubated with Alexa fluor
®
-conjugated secondary antibody 
(ThermoFisher Scientific, Rockford-USA) dissolved in 3% FBS, for 1 hour at RT in dark. After 
incubation, neurons were washed and stained with DAPI solution (1:10,000) for 5 minutes at RT at 
dark.                                                                                                                                                   
For the “two-stages” procedure neurons were incubated before fixation with 3% FBS for 30 minutes 
at 4°C and then incubated with the first primary antibody dissolved in 3% FBS for 30 minutes at 
4°C. After this incubation cells were washed with PBS briefly and standard immunofluorescence 
protocol was followed to label with the second primary antibody. This “two-stages 
immunofluorescence” allowed us to distinguish between extracellular and intracellular targets.                                                             
The coverslips were mounted with VECTASHIELD
®
 antifade mounting medium (Vector 
Laboratories). Stacked images were taken with a TCS SP2 laser scanning confocal (Leica 
Microsystems; Wetzlar-Germany) with a 63x oil objective. Immunofluorescence on SH-SY5Y was 
performed following the same procedure except that here cells were fixed with 3.7% PFA.                                   
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Table 2. Immunofluorescence antibodies. 
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5.8        TUNEL assay  
 
Neurons were fixed and permeabilized as previously described. They were washed with PBS first, 
and then with distilled H2O to equilibrate. They were then incubated with 1X Terminal 
Deoxynucleotidyl Transferase (TdT) Buffer (3 mM trizma base, 14 mM cacodylate sodium, 0.1 
mM cobalt chloride at pH 7.2) for 15 minutes at 37°C and subsequently with TdT reaction mixture 
(TdT buffer, 1mM Biotin-16-dUTP [Roche, Indianapolis-USA], 400 U/L terminal 
deoxynucleotidyl transferase [Roche, Indianapolis-USA]) for 1 hour at 37°C. In this way, the 
modified nucleotides are incorporated at the terminal of DNA broken strand. In order to prevent 
evaporation due to a small volume of TdT reaction mixture, the plate was placed into a box on wet 
absorbent paper. After incubation, to block the enzyme activity, neurons were washed with 2X 
Saline-sodium citrate (SSC) (Clontech, Mountain View, California-USA). Unspecific binding sites 
were blocked incubating for 30 minutes with 1% bovine serum albumin (BSA) and 0.1% Tx-100 at 
RT. Then neurons were incubated with 1:3,000 Streptavidin, Alexa Fluor® 568 conjugate 
(ThermoFisher Scientific, Eugene, Oregon-USA), that binds biotin of dUTP, for 1 hour at RT at 
dark. After incubation, neurons underwent five washes of 5 minutes each with 1X PBS, with 
shacking and incubated with primary (1:500 NeuN) and secondary antibody, accordingly to the 
immunofluorescence protocol. The Nikon Eclipse E600 epi-fluorescence microscope (©2007 Nikon 
Corporation) was used to take images. In detail I took a set of six images of DAPI, TUNEL and of 
NeuN staining for each treatment, using a 20x objective. Each picture was analyzed using ImageJ, 
software that allowed us to count precisely the number of living or dying cell.  
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5.9         The inducible cell model 
 
The creation of a cell model with S expressed in the ER could allow to mimic the situation in 
which the increase of S relocalization in the ER follows the onset of the pathology, as seen in the 
A53T S transgenic mice (Colla et al., 2012a). To establish a stable and inducible cell model of S 
expression I used human neuroblastoma cell line SH-SY5Y. To make cells inducible I exploited the 
tetracycline-regulated mammalian expression system (T-REx™ system, Invitrogen). The major 
components of the T-REx™ System are (Fig. 13): 
• a Tet-inducible expression vector, pcDNA4/TO, in which is cloned wild-type S sequence tagged 
with an ER localization signal (at the N-terminal), a retention signal (SEKDEL) and a Myc-tag 
(both of them at the C-terminal) under the control of the strong human cytomegalovirus (CMV) 
immediate-early promoter and two tetracycline operator 2 sites (TetO2). Each TetO2 sequence 
serves as binding site for two molecules of the Tet repressor. The selection marker is the gene for 
Zeocine
™
 resistance. 
• A regulatory plasmid, pcDNA6/TR©, which encodes for the Tet repressor (TetR) under the control 
of the human CMV promoter, that expresses the gene for blasticidin resistance as selecting marker. 
• The doxycycline to induce protein expression.  
In order to express S, the cells need to be stably harboring the two vectors above-mentioned. Only 
the cells expressing both plasmids produce S after doxycycline administration.                           
The insertion of the two plasmids has been done in two separate and sequential transfections. In the 
first transfection the cells received the vector codifying for the repressor protein (pcDNA6/TR). 
Positive clones that grew in presence of the selecting agent blasticidin were selected and expanded. 
The best clone has been then transfected with the second vector codifying for S. The cells that 
acquired this vector were selected by Zeocin™ administration. 
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Figure 13. Components of the T-RexTM system and mechanism of repression. The figure shows that 
without the inductor, Tet repressor forms a homodimer that binds with extremely high affinity to 
each TetO2 and the gene expression is repressed. Upon addition, tetracycline, or its analog 
doxycycline, binds with high affinity to each Tet repressor homodimer and causes a conformational 
change in the repressor that make it unable to bind to the Tet operator. The Tet 
repressor:tetracycline complex then dissociates from the Tet operator and allows induction of 
transcription of S. 
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Before each transfection, a survival curve of parental cells was done using different concentrations 
of the two selecting antibiotics (blasticidin and Zeocin™) and for each of them it was determined 
the minimum concentration required to kill non-transfected cells. The count of viable cells has been 
done at regular intervals within 1-2 days after addiction of antibiotics. In this case it has been 
established a concentration of 3 g/ml of blasticidin and 50 g/ml of Zeocin™, for the correct 
maintenance of two plasmids in cells. Once the cell line was stabilized, in order to un-repress the 
hybrid CMV/TetO2 promoter in the inducible expression vector and to induce transcription of S, 
cells were treated with 0.5 g/ml of doxycycline. This inductor has been used as an alternative of 
tetracycline, because it has been shown to have a longer half-life than tetracycline (48 hours vs. 24 
hours, respectively). They are similar in the mechanism of action and they exhibit similar dose 
response and induction characteristics. 
The cells were maintained using Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-Aldrich, 
St. Louis-USA) with 10% FBS, 0.1 mg/ml of streptomycin and 100 U/ml of penicillin. This 
medium contained FBS with a reduced amount of tetracycline, in order to avoid a basal expression 
of S in absence of antibiotic. Differentiation was induced by administration of 10 M retinoic acid 
(RA) in 1% FBS DMEM. 
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5.10   Statistical analysis 
 
The data collected from the immunoblots were analyzed with Student’s t test, using the software 
GraphPad Prism. The quantification was previously made using the Bio-Rad free software Image 
Lab. The data collected from cells immunostained with DAPI, NeuN and Tunel and counted 
exploiting the ImageJ software were analyzed with one-way ANOVA, using the software GraphPad 
Prism. It was then done the post-hoc Tukey test. Data from experimental groups are expressed and 
presented as mean of the control group ± standard error of the mean (S.E.M). A probability level of 
p<0.05 was taken as significant in each test. 
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6.     Results and Discussion 
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6.1  Biochemical characterization of S aggregates 
 
Since it has been shown the presence of S oligomers and aggregates in the ER membrane (Colla et 
al., 2012), the first step of the project has been the biochemical analysis of these aggregates 
associated with the microsomal/ER membranes of diseased and presymptomatic Tg mice (S 
A53T). The characterization aimed to show if distinct populations of S HMW species existed at 
the same time in neurons and then what type of post-translational modifications (PTMs) occurred 
there. In order to do that, I isolated two fractions of S aggregates (P10 and P100) from the same 
mouse SpC homogenate obtained from diseased A53T (Tg) mice using differential centrifugation 
speeds according to their sedimentation rate. P10 represents a crude membrane pellet fraction that 
sediments at 10,000 × g, should contain the majority of S aggregated species and is rich in 
mitochondria (Colla et al., 2012). P100 is the microsomal fraction, that sediments at 100,000 × g 
and is rich in ER, Golgi and synaptic vesicles. As control of the experiment, I isolated the P100 
fraction from the SpC homogenate obtained from non-transgenic (n-Tg) mice that should not have 
any type of aggregate. I also isolated the P100 fraction from the cortex (Ctx) homogenate obtained 
from the diseased mice. Although this latter tissue is pathology-free, it allows us to understand 
characteristic of S strains during the evolution of the disease. Furthermore, in order to show that 
different S species are correlated to the onset of the pathology, I use also the P10 and P100 
fractions from the SpC presymptomatic (9 months) aged mice. Initially to confirm if P10 and P100 
pellet fractions contained S aggregates I performed a dotblot analysis in which 2 g of P10 and 
P100 fractions were spotted onto nitrocellulose membranes that were then incubated with 
aggregates specific antibodies such as pser129-S, which recognize the phosphorylated form of the 
protein found in the LB and LN in PD brains, and Syn303 antibody, which recognizes the 
aggregated one (Fig. 14 a). This experiment determined that as expected only the affected tissue 
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(SpC) showed the presence of HMW S species, compared with the SpC of presymptomatic mice 
and with the Ctx of the diseased ones. Moreover it was interesting to see that the P100 
immunoreactivity to these two antibodies was higher than P10, suggesting an increased presence of 
S aggregates associated with the in the P100/Microsomal fraction. The graph (Fig. 14 b) shows 
relative density of HMW S species in P10 and P100 detected with pS129-S and Syn303, 
obtained by normalization respectively with LB509 antibody, that recognizes the human S 
monomer and Hu-syn antibody, that recognize the human form of the protein. Values are expressed 
as % of P10 and are given as the mean±SEM (n= 4) *p<0.05, Student’s t test. 
 
 
        
Figure 14. a) Dotblot of  HMW S species. Up: IB with pS129-S. Down: IB with Syn303. The 
larger amount of aggregates was found in the P100 fraction from sick mice. b) Graph for the 
amount of HMW S species compared to the total amount of S in the SpC of diseased mice. 
Values are expressed as % of P10 and are given as the mean±SEM (n= 4) *p<0.05, Student’s t test. 
 
 
a) b) 
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Then I analyzed if truncation of S, that is known to favor formation of S aggregates, was 
different in the two fractions of aggregates. 2 g of P10 and P100 fractions were run on a SDS-page 
and then transferred onto a nitrocellulose membrane. I detected the presence of truncated species in 
P10 and P100 using an antibody against the central portion of the protein, the NAC domain (Syn1 
clone 42) that recognizes the most common C-terminal truncated fragments and also the high 
molecular weight species (arrow) of S. Human S monomer was visualized with LB509 antibody 
that does not bind S aggregates, but only the monomeric form. The analysis of truncation showed 
how the accumulation of the most abundant and normally occurring C-terminal truncated fragment 
Syn12, Syn10 and Syn8 (Li et al., 2005) changed with the disease onset in P10 and P100 pellet 
fractions. In fact in the SpC of the diseased mice I saw the accumulation all the three above-
mentioned fragments of the protein (Fig. 15 a). In particular Syn8, is truncated at both N- and C- 
terminal and it is only found in S fibrils. In fact this fragment is absent in presymptomatic mice 
and in the Ctx of the diseased mice, confirming the lack of aggregation in these two areas.                                                      
The graph (Fig. 15 b) shows the relative amount of the truncated fragment in P10 and P100 fraction, 
obtained by normalization with LB509 antibody.  Values are expressed as % of P10 and are given 
as the mean±SEM (n= 4) ***p<0.0001, **p<0.001, *p<0.05, Student’s t test.                                       
Also in the case of presymptomatic mice, the immunoblotting was performed using Syn1. We only 
saw the accumulation of Syn12 in the P10 fraction (Fig.16 a). The amount of relative truncated 
specie was obtained by normalization with the Hu-syn antibody. Values are expressed as % of P10 
and are given as the mean±SEM (n=3) *p<0.05, Student’s t test (Fig. 16 b).  
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Figure 15. a) Immunoblotting of accumulation of S truncated fragments in P10 and P100 with 
Syn1. The figure shows the presence of all three truncated fragments. b) Graph of the amount of 
truncated fragment in the SpC of diseased mice. Values are expressed as % of P10 and are given as 
the mean±SEM (n= 4) ***p<0.0001, **p<0.001, *p<0.05, Student’s t test. 
 
 
 
 
 
 
a) b) 
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Figure 16. a) Immunoblotting of accumulation of S truncated fragments in P10 and P100 with 
Syn1. The figure shows the presence of only the Syn12 fragment. b) Graph of the amount of 
truncated fragment in the Spc of presymptomatic mice. Values are expressed as % of P10 and are 
given as the mean±SEM (n=3) *p<0.05, Student’s t test. 
 
                                               
 
 
 
 
b) a) 
* 
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Another immunoblotting was performed with Syn1 antibody, using the P100 fraction from the Ctx 
of diseased mice. The analysis shows an intermediate condition where P100 contained less Syn12 
fragment but more Syn10 as if Syn10 truncation was secondary to Syn12 digestion (Fig. 17 a). The 
graph (Fig. 17 b) shows relative density of S truncated fragments in P10 and P100 obtained by 
normalization with human S monomer. Values are expressed as % of P10 and are given as the 
mean±SEM  (n=3) *p<0.05, **p<0.001, Student’s t test. 
Thus the microsomal-containing P100 fraction shows an increase in S truncation compared to P10 
that is temporally and spatially linked to the disease onset and concurrent with S aggregation. 
Moreover we can hypothesize that Syn10 fragment is not a new fragment forming in the Ctx, but it 
derive from an additional fragmentation of Syn12 fragment.            
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Figure 17. a) Immunoblotting of accumulation of S truncated fragments in P10 and P100 with 
Syn1. The figure shows the presence of the Syn10 and Syn12 fragments. b) Graph of the amount of 
truncated fragment in the Spc of presymptomatic mice. Values are expressed as % of P10 and are 
given as the mean±SEM  (n=3) *p<0.05, **p<0.001, Student’s t test. 
 
 
 
 
 
* 
a) b) 
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I then analyzed aggregation-associated PTMs such as the phosphorylation of the Ser 129 and 
nitration of S. 2 g of P10 and P100 fraction were run on a SDS-page and then transferred on a 
nitrocellulose membrane. The immunoblotting was performed with pSer129-S antibody and 
human S monomer was visualized with Hu-Syn antibody. The analysis reveals that there is a 
significant increase of phosphorylated S in the P100 fraction, compared with the P10 fraction. 
This PTM occurred only in the SpC of diseased mice (Fig. 18 a).                                                                              
The amount of phosphorylated S specie was obtained by normalization with the Hu-syn antibody 
(Fig. 18 b). Values are expressed as % of P10 and are given as the mean±SEM (n=4) **p<0.01, 
Student’s t test.  
Also for S nitration, the different immunoblotting were performed, after a SDS-page in which 2 
g of proteins were loaded into the gel, using Syn514 antibody, that recognize the nitrated form of 
S (Fig. 19 a). The graphs (Fig. 19 b) show relative density of nitrated S in P10 and P100 
respectively in diseased Ctx and in presymptomatic SpC and diseased SpC, obtained by 
normalization with human S monomer. Values are expressed as % of P10 and are given as the 
mean±SEM  (n=3 or 4). **p<0.01, Student’s t test. n.s. not significant.                                                                                                             
The western blot analysis indicated that this modification was not pathology specific because it 
occurred also in the SpC of presymptomatic mice and in the Ctx of diseased ones. SpC from 
presymptomatic and diseased animals has comparable levels of nitrated S in P10 and P100 (Fig  
19 a). Contrarily, in the Ctx P100 fraction of diseased mice we can see lower levels of nitrated S, 
compared with the P10. It is reasonable to think that the nitration has a specific-tissue pattern rather 
than a correlation with the onset of the pathology. Thus the experiments show that S nitration is 
not pathology specific, contrarily as regard the phosphorylation, that occurred only in the SpC of 
diseased mice.  
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Figure 18. a) Immunoblotting of accumulation of S phosphorylated  in P10 and P100 with pS129-
S. The figure shows an increase of phosphorylation in P100 fraction. b) Graph of the amount of 
phosphorylation in the Spc of diseased mice. Values are expressed as % of P10 and are given as the 
mean±SEM (n=4) **p<0.01, Student’s t test. 
 
 
 
.                                                                               
 
 
a) b) 
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Figure 19. a) Immunoblotting of accumulation of S nitrated in P10 and P100 with Syn514. b) 
Graph of the amount of nitration in the SpC of diseased and presymptomatic mice and in the Ctx of 
the diseased mice. Values are expressed as % of P10 and are given as the mean±SEM  (n=3 or 4). 
**p<0.01, Student’s t test. n.s. not significant.  
 
 
                       
 
 
 
Sick Spc 
a) b) 
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Finally, these experiments represent a first accurate characterization of the two S aggregates 
populations. Together the experiments suggest that specific features such as increased aggregation, 
truncation and phosphorylation can define a distinctive S population associated with the 
microsomal vesicles. It is not already clear if the aggregates found in the P10 fraction derived from 
the accumulation of those associated with the ER membrane. 
 
 
6.2   Internalization of S aggregates fractions in mouse primary hippocampal 
and cortical  neurons 
 
Once the characterization has been done, I asked if P10 and P100 fractions had any cytotoxic effect 
when administered to neuronal cultures. In order to do that I followed a protocol established by 
Virginia Lee and coworkers where it was shown that neurons can internalize preformed in vitro 
assembled S fibrils in culture (Volpicelli-Daley et al., 2011). Thus I dosed P10 and P100 fractions 
directly in the conditioned medium of hippocampal and cortical primary neurons obtained from 
WT-mice and performed cytotoxic assays. To avoid sample variability, P10 and P100 fractions 
were pooled after purification from 3 or 4 mice. At day in vitro (DIV) 7 0.5 g of the following 
pellet fractions was given to neurons, that were seeded into a 24-well plate: 
 P10 and P100 from SpC of diseased mice, 
 P10 and P100 from SpC of presymtomatic mice, 
 P100 from Ctx of diseased mice, 
 P100 from SpC of n-Tg littermates (as control). 
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After 2 weeks of treatment, hippocampal neurons were fixed. Immunostaining with Syn303 or 
pS129 revealed the formation of small chain-like structures. In fact the administration of 0.5 g of 
P100 fraction from SpC of sick mice resulted after 2 weeks of treatment in the appearance of beads-
like structures (strings), organized in a neurite-like manner, positive for S aggregates specific 
antibodies such as Syn303 and pS129-S. The administration of 0.5 g of P10 from SpC of 
diseased mice failed to produce any type of structure (Fig. 20  a-b). Further application of 
increasing amount of aggregates to the neurons resulted in an increased formation of unique S 
structures. Dosing 1 g of P100 from the SpC of sick mice produced after two weeks the 
appearance of longer and more mature strings, that spread following a neuritic pattern and that were 
still positive for aggregates-specific antibodies. When 1 g of P10 fraction was given to the 
neurons, some small puncta or bead-like structures appeared. While for P100 those structures were 
more organized and stained an entire segment of the neurite, for P10 these structures were more 
immature and comparable in size to what obtained when P100 sick was administered at lower 
concentration (Fig 20 c-d). When 2 g of P100 fraction was given to the neurons structure bead-like 
localized along the neurites, but also they begin to accumulate in the soma of the neurons and then 
in the nucleus (Fig. 20 e). These structures did not occur when P10 and P100 from presymptomatic 
mice or P100 from Ctx and n-Tg were administered to neurons or when neurons were only treated 
with PBS as control, showing that Syn303 or pser129-S labeling was specific for P10 and P100 
from diseased mice (Fig. 21-22). The Figure 22 shows that the administration of P100 from Ctx and 
n-Tg littermates or P10 and P100 fractions from presymptomatic mice did not trigger the formation 
of any type of strings made of S. This time neuronal cultures were treated with 1 g of P10 and 
P100 from presymptomatic SpC or P100 from sick Ctx or P100 from n-Tg littermates SpC and 
fixed after 2 weeks. Double-immunostaining with Syn303 and Mouse-S showed only the signal of 
the mouse-S was evident, showing that neuronal network was intact and well, but not the signal 
due to the presence of the aggregates.                                                                                                                                                              
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Figure 20.  Immunostaining of hippocampal neurons with Syn303 (a-b-c-d) and with pS129-S (e). 
The confocal images show internalization and deposition of S positive structures after 
administration of increasing amount of P10 and P100 fractions obtained from diseased mice. In a)-
b) the neurons were administered with 0.5 g of P10 and P100 fractions, respectively. In c)-d) the 
neurons were administered with 1 g of P10 and P100 fractions, respectively. In e) the neurons 
were administered with 2 g P100 fraction. Scale bars, 20 m. 
             
              
Figure 21. Double-immunostaining of hippocampal neurons with Syn303 and Map2. The confocal 
images show the lack of any type of Syn303 positive structures when neurons were only treated 
with PBS. Scale bar, 20 m. 
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Figure 22. Double immuno-staining of hippocampal neurons with Syn303 and M-Syn. The 
confocal images show the lack of any type of Syn303 positive structure in P100 fraction from Ctx 
of diseased mice and from SpC of n-Tg littermates and presymptomatic mice and in the P10 
fractions from SpC of presymptomatic mice. Scale bars, 20 m. 
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Initially the S strings localized at the axon terminal of neurons. After two weeks double 
immunofluorescence with Syn303 and an axonal marker Tau or Syn303 and a dendrite marker 
Map2 was carried out. Confocal microscopy revealed that bead-like structures produced by 
internalization of P100 co-localized with axonal marker Tau but not the dendrite marker Map2 (Fig. 
23).  
 
 
             
 
Figure 23. a) Double-immunostaining of cortical neurons with Syn303 and Tau. The confocal 
image shows that Syn303 positive structures co-localize with the axon marker Tau. b) Double-
immunostaining of hippocampal neurons with Syn303 and Map2. The confocal image shows that 
there is no overlapping between Syn303 positive structures and the dendrites marker Map2. Scale 
bars, 20 m. 
 
 
In order to see if effectively the aggregates were internalized by neurons or simply bound outside 
the plasma membrane, I performed a “two-stages” immunocytochemistry assay (Fig. 24).                            
In this case I incubated hippocampal neurons still alive, that means before the fixation, at 4 C° for 
a) 
b) 
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30 minutes, with pS129-S antibody. With the plasma membrane intact only aggregates that have 
not been internalized were labeled. I then fixed and permeabilized the cultures and co-stained for 
Syn303 to label all the aggregates (as regard the cells administered with P100 fractions from SpC of 
diseased mice, Fig. 24 a). In the control situation (Fig. 24 c), in which I did not administered any 
type of aggregates to the cells, the hippocampal neurons were incubated before the fixation with 
Map2 antibody. The second antibody administered in this case was Mouse-S. In order to test the 
precision of the technique, I performed another assay on untreated neurons, in which the first 
antibody used was Grp94, that recognizes an ER chaperone. Then the second antibody used was 
Syn1 (Fig. 24 b). As shown in the Figure 24 a, all the P100 aggregates were labeled only with 
Syn303 but not with pS129-S, showing that P100 aggregates have been internalized. If the 
aggregates were labeled to the membrane and so they were outside the cells, I should see also the 
pS129-S signal. Lack of signal was not due to the steric hindrance of the two antibodies (see 
Figure 30). The Figures 24 b-c show only the signals of the second antibody administered. This fact 
demonstrate that effectively the antigens recognized by Grp94 and Map2, respectively, were into 
the cells.  
Together these experiments demonstrate that the P100 fraction from the SpC of the diseased mice is 
the more toxic within the entire aggregates population. Nevertheless, I showed that the 
administration of an increase amount of P10 fraction from the SpC of diseased mice triggers the 
formation of bead-like structures. In fact, it was interesting to note that the application of different 
amount of aggregates to the neurons implicated also the formation of unique S structures.                                                     
In conclusion, P100 fractions from the SpC of the diseased mice, containing microsomal-associated 
S aggregates, were taken up by neurons and spread into string-like structures, following a neuritic 
pattern that co-localized with axonal markers.  
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Figure 24. a) Double-stage immunofluorescence with pS129-S and Syn303 on hippocampal 
neurons. The confocal images show that the aggregates localize into the cells. b) Double-stage 
immunofluorescence with Grp94 and Syn1 on hippocampal neurons. The confocal images confirm 
that the ER marker is into the cells. c) Double-stage immunofluorescence with Map2 and Mouse-
Syn on hippocampal neurons. The confocal images show the presence of only MSyn signal. 
Scale bars, 20 m. 
 
 
a) 
b) 
c) 
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6.3  Induction of apoptosis in mouse cortical primary culture treated with P100 
from SpC of presymptomatic and diseased mice 
 
Primary cortical neurons were treated with 2 g of various P10 and P100 fractions obtained from 
presymptomatic and diseased SpC or Ctx of Tg mice and age-matched n-Tg. Cultures were fixed 
after 4 days of treatment and labeled with NeuN, as neuronal marker and with TUNEL staining as a 
measure of apoptosis. Every single culture was first double-labeled with TUNEL staining and then 
with NeuN antibody. Cells were also counterstained with DAPI. P100 fraction from SpC of 
diseased mice is more toxic if compared both to the P10 fraction and to untreated (Ctr). Only 
primary cultures treated with P100 fractions obtained from affected tissues of diseased mice and 
more surprisingly from presymptomatic littermates showed cellular death as soon as 24-48 hours 
after administration (Fig. 22). I could observe minimal levels of neuronal degeneration in cultures 
treated with P10 from sick and presymptomatic mice, P100 Ctx or P100 n-Tg comparable to 
untreated cells. Although TUNEL levels were comparable between presymptomatic and sick P100 
fractions, NeuN-positive neurons were actually in a larger number in presymptomatic P100-treated 
samples, rather than in sick P100-treated samples, suggesting that S species associated with 
microsomal fractions obtained from healthy aged animals were less aggressive in inducing cellular 
death.                                                                                                                                                    
The images of the three staining were acquired and the NeuN- or TUNEL- positive cells were 
counted with ImageJ. The graphs represent dead TUNEL-positive neurons (Fig. 22 a) and live 
NeuN-positive neurons count (Fig. 22 b) normalized for the number of Dapi-positive nuclei. Values 
are expressed as % of untreated neurons (Ctr) and are given as the mean±SEM  (n=6) **p<0.001, 
***p<0.0001, ****p<0.00001, ANOVA test; Tukey post-hoc test.   
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In the Figure 25 a, it can be noticed that the higher levels of cell death are given by the 
administration of P100 fraction from SpC of diseased mice. The administration of P10 fraction from 
SpC of sick mice induces less cells death compared with the P100 fraction of presymptomatic mice. 
The Figure 25 b shows that the neuronal survival mainly occurs in the cells treated with the P10 
fraction from the SpC of sick mice, with the P100 fraction from SpC of n-Tg littermates and with 
the P100 fraction from Ctx of sick mice. Although the biochemical characterization of the 
aggregates showed that P100 fraction from SpC of presymptomatic mice did not reveal the presence 
of phosphorylated S or of Syn8 fragments as in the P100 fraction from sick mice, the graph 
underlies that cells death occurs after their administration. This fact encouraged to deepen the 
characterization of P100 fraction from SpC of presymptomatic mice. Surprisingly, I found S 
oligomers in some of the pool samples. The detection has been done using the oligomer-specific 
antibody A11, in a dotblot assay, in which 2 g of aggregates were spotted onto nitrocellulose 
membrane (Fig. 26).  
Thus only microsomal fractions obtained from diseased or presymptomatic animals have an 
enhanced ability to induce cellular death in primary neuronal cultures. So S structures that form in 
the initial phases of the aggregation process might contribute to the acquired toxicity of P100 
presymptomatic samples in cultured neurons.                                            
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Figure 25. a) Apoptosis in cortical neurons. b) Survival in cortical neurons. Values are expressed as 
% of untreated neurons (Ctr) and are given as the mean±SEM  (n=6) **p<0.001, ***p<0.0001, 
****p<0.00001, one-way ANOVA test, followed by post-hoc Tukey test. 
 
                                                                       
 
Figure 26. Immunoblotting of accumulation of S aggregates in SpC Pres with A11.                   
 
       
          
 
a) b) 
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6.4   Internalization of S aggregates fractions in cell models of S aggregation 
  
 
Because of the toxic effect of P100/M pellets in neuronal primary culture we asked if similar effect 
could be proven also in immortalized cell lines overexpressing S. 
In order to do that we first established a stable and inducible cell model of S expression in the ER. 
The protein can reach this location thanks to the presence of an ER localization signal and of a 
retention signal. I chose to express S in the ER in order to mimic the situation in which the 
localization of S in the ER follows the onset of the pathology. In fact while cultured neurons 
represent a more accurate model of neuronal physiology, still the procedure to acquire them is time 
consuming and depends on the availability of newborn pups. Thus immortalized cell lines can be 
very useful when and if they can recapitulate pathological phenomena seen in PD pathology. 
 
6.4.1 Creation of a stable and inducible cell model for the endogenous expression of WT 
S 
 
In order to create a stable and inducible model for S expression, I exploit the SH-SY5Y human 
neuroblastoma cells. Because these cells possess many characteristics of dopaminergic neurons, 
differentiating into this phenotype after RA administration, they have been used as dopaminergic 
neuronal model for PD research since several years (Xie et al., 2010). The cells (now I will call 
them SH-S WT) express the WT S in the ER, because they have been transfected with an 
expression vector in which is cloned the WT S gene, tagged with an ER localization signal and an 
ER retention signal. Since the model is inducible, the S expression is possible only after 
doxycycline administration. Expression level of S was tested after differentiation and induction 
with doxycycline in a time course manner (Fig. 27).   
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Cells were seeded in 6-well plate and differentiated and induced with RA (10 M) and doxycycline 
(0.5 g/ml) respectively at different times. Cells were collected at each time point.                          
To see if overexpression of S resulted in the appearance of insoluble and aggregated S species, 
cell lysates were fractionated, according to their solubility to the ionic detergent Tx-100. According 
to this protocol, soluble proteins such as S will end up in the Tx-S fraction and the Tx-Pellet (Tx-
P) fraction will contain insoluble and/or aggregated S. 5 g of Tx-S fraction and 10 g of Tx-P 
fraction were run on a SDS-page and then transferred onto nitrocellulose membranes. 
Immunoblotting with Syn1 antibody showed there is a low S expression without induction both in 
Tx-S and in Tx-P, where S is significantly soluble (Fig. 27 a). The graph in Figure 27 b shows the 
relative density of S in Tx-S and Tx-P respectively without or with doxycycline. The amount of 
S was obtained by normalization with -Tub. Each column of the histogram represents a single  
band of the immuno-blot. Addition of doxycycline induces the expression of S of 2-3 fold without 
affecting largely its solubility as shown by the increased expression in the Tx-S but not in Tx-P. We 
also noted that differentiation with RA in absence of doxycycline induce a low S expression, 
higher than control cells, probably due to a weak leakage of the promoter repressor used in the T-
Rex system. 
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Figure 27. a) Immuno-blotting of the S expression in two different cells fraction (Tx-S and Tx-P) 
and in two experimental conditions (-dox and +dox) with Syn1 and -Tub. b) Graph for the amount 
of S in Tx-S and Tx-P, with or without induction. Each column of the histogram corresponds to a 
band of the immuno-blotting.  
 
 
 
 
 
 
a) b) 
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S expression was also confirmed by immuno-staining with Syn1 (Fig. 28). Cells were induced a 
day after the plating with doxycycline and expression was assayed after 72 hours. Although cell 
colony was not pure and some cells did no express S, about 70-80% of cells analyzed showed 
inducible S expression after doxycycline administration.   
 
                              
Figure 28. Immuno-staining on SH-S WT with Syn1. The left panel shows that without 
doxycycline induction there is a minimal S expression. The right panel shows a large S 
expression after doxycycline induction. Scale bar, 20 m. 
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6.4.2   Internalization of S aggregates fractions in SH-S WT 
 
After obtaining a stable and inducible cell line for S expression we tested if administration of P10 
and P100 fractions were toxic. To do that cells were differentiated and induced for 3 days before 
fractions were dosed in the culture media. Again to avoid sample variability, single fractions were 
pooled from purified pellets obtained from 3 or 4 mice. Also in order to increase the chance of 
cellular absorption, cells were treated with 0.1 g/mL WGA, an inductor of endocytosis, together 
with 5 g of P10 or P100 fractions. Cells were analyzed 1 day after the treatment. Two-stages 
immunofluorescence was performed to see if the aggregates were actually internalized into the 
cells. The Figure 29 a shows the untreated cells (Ctr). The cells were incubated before the fixation 
with Grp94 antibody, that recognizes an ER chaperone, at 4 C° for 30 minutes, then with Myc 
antibody, that recognize the S. We can see that there is no signal due to the binding of Grp94, 
because this is located into the cell. The cells previously treated with the P10 and P100 fractions 
from SpC of diseased mice were incubated before the fixation with pS129-S antibody, against the 
aggregates. After the fixation the cells were incubated with Myc antibody. The Figures 29 b and c 
show that the administration of P10 and P100 fractions respectively from SpC of sick mice triggers 
the formation of S aggregates, accumulating out of the cells membrane. I could see the pS129 
signal because of the presence of the aggregates on the plasma membrane, as when the cells were 
incubated with this antibody, the membrane was intact. This was also demonstrated by repeating the 
two-stages immunofluorescence experiment and double-labeling cells with two antibodies against 
aggregates, pS129-S and Syn303 (Fig. 30). In this experiment I incubated the cells still alive with 
pS129-S antibody and then after fixation with Syn303. The figure shows the co-localization of the 
two antibodies, confirming that the aggregates are on the plasma membrane and not internalized by 
cells. If the aggregates were into the cells, we did not obtained the pS129-S signal.                                                            
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Figure 29. Double-stage immunofluorescence on SH-S WT with Grp94 and Myc in a), pS129-S 
and Myc in b)-c). The confocal images show that the aggregates formed cannot enter the cells. 
Scale bars, 20 m. 
 
 
a) 
b) 
c) 
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Figure 30. Double-stage immunofluorescence on SH-S WT with pS129-S and Syn303. The 
confocal image show that there is overlapping between phosphorylated S out of the membrane and 
the Syn303 positive structures. Scale bar, 20 m. 
      
Detection of pS129 signal for P10 and P100 (Fig. 29 b-c) demonstrated that on the contrary of 
neuronal cultures, here S aggregates were not internalized by neurons. This was not due to the 
passive transport of the pS129 antibody, because we could not detect any merged signal. Some 
experiments were also performed administering the Pro-DeliverIN™ reagent together with the 
aggregate. The reagent is a formulation of lipids able to capture proteins and deliver them into the 
cells. The results reached were the same compared with those of the afore-described experiments 
(data not shown). The lack of aggregates internalization might be due to the absence of the 
transmembrane protein lymphocyte activation gene-3 (LAG3) in SH-S WT. In fact, it has been 
recently shown that LAG3 mediates the internalization of S fibrils in neurons (Mao et al., 2016). 
Even if this is not the best model to study the transport and the internalization of S aggregates into 
the cells, it could be a good model of aggregation. In fact, thanks to the S expression in the ER, 
after administration of doxycycline, this model can be exploited to study the ER stress and the 
resulting cytotoxic effects.  
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7. Conclusion and future perspectives 
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The results just described show the peculiar characteristics of S aggregates obtained from the 
A53T mutant human S Tg mouse model. They demonstrate that within the whole population of 
S HMW species the S strains associated with the microsomal membranes are a unique 
population with specific biochemical traits and are the most aggressive in terms of propagation and 
neuronal degeneration. Thus it seems that at least two different populations of S species exist in 
diseased neurons at the same time in a Tg mouse model of PD. Also the finding that 
presymptomatic mice already showed toxic S strain before disease onset would suggest that S 
aggregation might initiate first in close proximity to the ER/microsomal membrane (Lee et al., 
2002; Snead et Eliezer, 2014). Many questions arise from these findings: 
 Where aggregation starts?  
 Are the two populations (in the P10 and P100 fractions) of S related?  
 Do they form at the same time or one of them is the consequence of the other one? 
 What is the ultrastructure of these aggregates? 
Thus, more studies will be necessary to see if such S strains as the one described in this work, 
exist in other PD models or human brains and behave in the same way. Once fully characterized, αS 
strain associated with the microsomal membranes could represent a new target for therapeutic 
intervention. 
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